Silence Therapeutics plc — Investor Relations & Filings

Silence Therapeutics plc is a clinical-stage biotechnology company pioneering the design and development of medicines based on short-interfering RNA (siRNA). The company utilizes its proprietary technology platform to create precision-engineered therapies that selectively silence the expression of disease-causing genes. Its clinical pipeline focuses on addressing conditions with high unmet medical needs in therapeutic areas such as cardiovascular disease, hematology, and rare diseases. Key product candidates in development include zerlasiran, targeting cardiovascular risk, and divesiran for polycythemia vera. The company aims to provide transformative treatments for patients who have limited or inadequate therapeutic options.